Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CCI begins public...

    CCI begins public consultation on Bayer-Monsanto deal

    Written by Ruby Khatun Khatun Published On 2018-01-07T10:00:56+05:30  |  Updated On 7 Jan 2018 10:00 AM IST
    CCI begins public consultation on Bayer-Monsanto deal

    New Delhi: Fair trade regulator Competition Commission (CCI) launched a public scrutiny of finer details of the proposed USD 66 billion Bayer-Monsanto deal, which would create the world's largest seeds and pesticide firm.


    The comments with respect to the Bayer-Monsanto deal need to be submitted to the Competition Commission of India (CCI) within 15 days, along with supporting documents on how the merger can adversely impact the concerned person or entity, the CCI said in a public notice.


    It further said that "the Commission is not likely to consider unsubstantiated objections".


    The CCI places a deal for public consultation if it is of the "prima facie opinion that the combination has, or likely to have an appreciable adverse effect on competition".


    Prior to this, the fair trade regulator had launched similar public scrutiny in the case of Ranbaxy-Sun Pharma and Holcim-Lafarge merger deals, among others.


    The deal between Bayer-Monsanto, both of which have a good presence in India, was announced in September 2016.


    On September 14, 2016, Bayer and Monsanto entered into a definitive agreement and plan of merger by which the entire shareholding of Monsanto will be acquired by Bayer.


    As a result of the proposed combination, Monsanto will become a wholly-owned subsidiary of Bayer.


    Bayer operates in pharmaceuticals, crop science, consumer health and animal health with a broad range of products in each division. While, Monsanto is a sustainable agricultural company engaged in the production of agriculture and vegetable seeds, herbicides/weed control solutions.


    As per a notice filed by Bayer before the CCI in October 2016, the "proposed combination raises no competitive concern in any of the overlap products".


    In India, both entities have the presence in production and sale of vegetable seeds, cotton seeds as well as in production and sale of non-selective herbicides, according to that notice.


    The parties believe that the proposed combination does not give rise to competition concerns regardless of the manner in which the markets are delineated.


    "The parties are engaged in complementary business practices and the proposed combination seeks to capitalize on the synergies arising as a result of the complementaries. The parties, therefore, believe that it is not necessary to definitely conclude on market definition for the purposes of the proposed combination," as per Bayer.


    Bayer expects the proposed combination to close by early this year.

    BayerBayer-Monsanto dealbeginsCCICompetition CommissionCompetition Commission of Indiadealdefinitive agreementHolcimLafargemergerMonsantopublic consultationpublic noticeRanbaxySun Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok